Category: Emerging risks · Reviewed by Taylor Watts, Broker · New Business · Last reviewed 2026-06-10
Gene editing risk insurance is a class of life sciences insurance providing product liability, clinical trial, professional indemnity and bodily injury cover for organisations developing, manufacturing or administering genome-editing therapies, agricultural products and research tools, principally those using CRISPR-Cas9 and successor systems.
Genome editing in the United Kingdom is regulated through a tiered framework distinguishing human reproductive use (prohibited save in narrow research circumstances under the Human Fertilisation and Embryology Act 2008), human somatic and therapeutic use (regulated by the Medicines and Healthcare products Regulatory Agency under the Human Medicines Regulations 2012 and the Medicines for Human Use (Clinical Trials) Regulations 2004), and precision-bred plants and animals (Genetic Technology (Precision Breeding) Act 2023). The insurance market has responded with bespoke wordings underwritten at Lloyd’s and by specialist life sciences carriers.
Definition
Gene editing risk insurance comprises:
Clinical trial insurance complying with ABPI Clinical Trial Compensation Guidelines and MHRA requirements.
Product liability for licensed cell and gene therapies (advanced therapy medicinal products, ATMPs).
Professional indemnity for genetic counsellors, clinical geneticists and laboratory directors.
General and product liability for agricultural and industrial applications.
Research and laboratory liability including contained-use containment failure.
It overlaps with broader life sciences cover but features specific exposures arising from heritable changes, off-target effects and long-tail latent injury.
Legal and regulatory basis
The UK statutory and regulatory framework includes:
Human Fertilisation and Embryology Act 2008 — governs human embryo research and prohibits implantation of genetically altered embryos in a woman save under specific licence.
Human Medicines Regulations 2012 (SI 2012/1916) — marketing authorisations for ATMPs.
Medicines for Human Use (Clinical Trials) Regulations 2004 (SI 2004/1031) — informed consent and trial sponsor liability.
Genetic Technology (Precision Breeding) Act 2023 — distinguishes precision-bred organisms from GMOs for plants and animals in England.
Consumer Protection Act 1987 — strict liability for defective products.
FCA Handbook ICOBS and PROD 4 — distribution standards for the placement of these policies (see ICOBS).
How it works in practice
A typical placement involves:
Risk survey of editing platform, target indications and off-target validation.
Underwriting submission including IND/CTA documentation, manufacturing chain (GMP) status and bioethics committee approvals.
Layered programme — primary clinical trial limit at GBP 5 million to 10 million, with excess product liability layers in the Lloyd’s and Bermuda markets.
Wording bespokery — explicit treatment of germline editing exclusions, off-target liability and long-tail latency.
ATMP product liability is generally written on a claims-made basis with extended reporting endorsements reflecting the 30-year follow-up obligations under the European Medicines Agency framework retained in UK law.
Common variations and subsequent developments
Casgevy precedent — the MHRA’s November 2023 conditional marketing authorisation of exa-cel (Casgevy) as the first CRISPR-based therapy approved in the UK has shaped subsequent underwriting.
Precision breeding plants — regulations under the 2023 Act commenced for plants in England in 2025.
Heritable editing exclusion — most policies exclude liability for intentional heritable germline modification.
No-fault compensation — interest in pooled no-fault arrangements analogous to vaccine damage payments.
Example
A UK biotechnology company conducts a Phase II clinical trial of a CRISPR-Cas9 ex vivo therapy for sickle cell disease. Its clinical trial insurance follows ABPI guidelines and provides no-fault compensation for participants, with limits of GBP 10 million any one trial. Product liability cover, taken at the point of conditional marketing authorisation, sits on a 30-year extended reporting endorsement to address latent oncogenicity risk. The placement excludes any application in human reproductive cells, consistent with the Human Fertilisation and Embryology Act 2008.
EMA, “Guideline on follow-up of patients administered with gene therapy medicinal products” (EMEA/CHMP/GTWP/60436/2007).
This entry is part of the Apex Insurance Wiki. Last reviewed by Matt Bartlett on 2026-06-10. Next review: 2026-12-10.
Apex Insurance Brokers Limited. Authorised and regulated by the Financial Conduct Authority, FRN 724952. Registered in England and Wales, Companies House 07014570. This entry provides general information about UK insurance concepts and is not regulated advice. Consult your insurance broker on your specific position.
Our service promise. We acknowledge every quote request the same working day. For straightforward risks, indicative terms typically follow within five working days. Complex risks — higher-risk buildings, cladding, mid-term proposals requiring fresh underwriting — may take longer; we’ll send you a progress note by the end of the fifth working day in those cases.